Aloperine inhibits RANKL-induced osteoclast differentiation via suppressing the MAPK signaling pathways

To figure out the molecular mechanism of aloperine (ALO) on receptor activator nuclear factor (NF)-kappa-B (κb) ligand (RANKL)-caused osteoclast differentiation. The histopathological analysis and tartrate-resistant acid phosphatase (TRAP) staining assays were applied to check extent bone loss femur. Then, protein expressions nitric oxide synthase 2, glutathione reductase, erythroid 2-related heme oxygenase-1, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 1, catalase checked in RAW264.7, a macrophage cell line, by enzyme-linked-immunosorbent serologic assay Western blot analysis. Further, TRAP quantitative polymerase chain reaction characterize level RAW264.7 Besides, was used extracellular regulated kinases (ERK), c-Jun N-terminal kinase (JNK), P38 RAW264.7. Finally, ERK activation blocker U0126 inhibit mitogen-activated (MAPK) signaling pathway determine effect MAPK In this study, results demonstrated that ALO could lipopolysaccharide-induced vivo dose-dependent manner, with significant inhibitory effects at high doses. Further research indicated RANKL-induced oxidative stress differentiation inactivate pathway. showed inhibition increase RANKL-caused inhibits suppressing pathways.